



SCHOOL OF PHARMACY

2ND QUARTER | JUNE 2026

MINER _{Rx} NUGGET

Updates for the preceptors of the University of Texas at El Paso School of Pharmacy

Contents

ANNOUNCEMENTS.....	P.2	CORE ELMS CORNER.....	P.4
PRECEPTORS OF THE YEAR.....	P.3	FEATURED ARTICLE.....	P.5

UTEP School of Pharmacy 2026 Graduating Class



On May 15th 2026 the School of Pharmacy celebrated it's 6th cohort.

Congratulations Class of 2026!

Calendar:

Aug. 11th - PET Quarterly Meeting

Aug. 24th - Fall Classes Begin

Sep. 7th - Labor Day (University closed)

Upcoming Rotation Dates:

2026 Summer IPPE

Jun. 29 - Jul. 10: IPPE Block 3

July 13 - 24: IPPE Block 4

July 27 - Aug. 7: IPPE Block 5

Aug. 10 - 21: IPPE Block 6

2026-27 APPE


July. 6 - Aug. 14: APPE 2

Aug. 17 - Sep. 25: APPE 3

Sep. 28 - Nov. 6: APPE 4

Nov. 9 - Dec. 18: APPE 5

Update your calendar:
Send us your events!



Announcements



Calling for 2026 Fall Didactic IPPE Availability



We are currently calling out for 2026 Fall Didactic Availability. Fall Didactic rotations run from August 24th until December 6th.

To submit your Fall Didactic availability, please complete the survey at the link below. If you have any question or need assistance submitting your availability, please don't hesitate to contact the OEE department at exedpharmacy@utep.edu and we will be happy to assist you.

[Availability Survey](#)



Pharmacist CEImpact Course Highlight

As an active UTEP SOP preceptor, OEE encourages you to take advantage of the on-demand continuing education courses in CEImpact. The new [2026 CEImpact access code](#) and a list of [TCEP approved CEImpact courses](#), are located in the Preceptor Resources section of your CORE ELMS home page. We would also like to highlight three courses below which are essential to renewing your TSBP license.

- [Topic Discussions to Promote Learner Growth](#) - 1hr On-Demand - FREE
- [Precept2Practice: Designing High-Impact Rotation Experiences for Pharmacy Learners](#) - 1hr On-Demand - FREE
- [Precept2Practice: Failure to Fail](#) - 30 Mins Podcast - FREE
- [Precept2Practice: Building Clinical Reasoning Skills in Student Pharmacists and Residents](#) - 30 Mins Podcast - FREE

Thank you Preceptors!

2025-26 Preceptors of the Year

It is our pleasure to recognize the recipients of the Preceptor of the Year Award for the 2025-26 Academic Year.



Dr. Brisa Chacon
Walgreens
Pharmacy


**IPPE Community
Preceptor of the Year**



Dr. Jin Kang
UMC Surgical
Hospital

**IPPE Hospital
Preceptor of the Year**

Dr. William Campillo
Terrazas
UTEP School of
Pharmacy
**APPE Faculty
Preceptor of the Year**



Dr. Jacob Alvarado
William Beaumont
Army Medical Center
**APPE Non-Faculty
Preceptor of the Year**



Want to get more involved?

Join our Preceptor Excellence Team!

The Preceptor Excellence Team is a great way to be more involved with efforts focusing on developing, recruiting, retaining, evaluating and recognizing preceptors. Reach out to Amanda Loya at amloya1@utep.edu if you are interested in being part of the PET.



This is a quarterly publication of the UTEP Office of Experiential Education/Preceptor Excellence Team.
We'd love to hear from YOU - Please send article ideas, events, awards/achievements/celebrations, or reach out to us if you are interested in becoming more involved.
Contact the OEE/PET: exedpharmacy@utep.edu

CORE ELMS Corner

UPDATES TO APPE ROTATION EVALUATIONS

Welcome to the start of the 2026-27 academic year! We would like to inform you about an important update to the APPE student evaluations which has gone into effect for the current academic year, 2026-2027.

APPE Rotation Evaluation: (Advanced Community, Advanced Hospital, Ambulatory Care, & In-Patient Gen Med)

Two additional questions have been included towards the end of the evaluations for the four core rotations and as noted within the evaluation, do not impact the student's grade and are not visible to the student.

Q1: Would you trust this student to be the pharmacist of a friend or loved one? (Yes/No)

Q2: On a scale of 1-10, (1 being lowest and 10 being the highest,) how would you rank this student's overall performance on rotation?

These questions are intended to serve as an additional touchpoint for our team to capture early impressions or "gut checks" that may not be reflected in the existing competency framework. In some cases, a student may meet formal criteria but still raise subtle concerns that are difficult to quantify. This addition allows those observations to be documented. The goal is to help identify students who may be struggling earlier and enable more timely support.

Again, these questions will not impact the student's grade and will not be visible to students in submitted evaluations. However, please note that if you show your screen to students during evaluations, they may be able to see your responses. Therefore, if you have concerns about a student seeing them, you may choose to complete the questions afterwards.

Evaluation Instructional Video:

To assist in completion of the APPE evaluations with the newly added questions, we have updated the instructional video at the link below for your viewing.

- APPE Final Evaluation - <https://utep.yuja.com/v/APPEFinalEval2026>

The screenshot displays the 'Pilot Questions' section of an evaluation. It includes a header 'Pilot Questions' with a 'Section Weight: 0%' indicator. Below the header, there is a detailed explanation of the pilot questions and a 'CONFIDENTIAL' warning. The first question, 'Question #1: On a scale of 1-10, 1 being lowest and 10 being the highest, how would you rank this student's overall performance on rotation?', is shown with a dropdown menu and a 'Required Final' label. The second question, 'Questions #2: Would you trust this student to be the pharmacist of a friend or loved one?', is also shown with a dropdown menu and a 'Required Final' label. The interface includes 'ADD QUESTION' and 'EDIT SECTION' buttons.

Featured Article

FDA Clears the Way for First Generic Single-Dose Flu Treatment Ahead of 2026 Season

Published on June 18th 2026 by [Pharmacy Times](#)

“On June 17, 2026, the FDA announced a significant milestone in public health with the approval of the first generic version of baloxavir marboxil (Xofluza; Genentech) tablets. Developed by Norwich Pharmaceuticals, Inc, this approval introduces a more affordable, single-dose option for the treatment of acute uncomplicated influenza and post-exposure prophylaxis in patients aged 5 years and older.¹

A Timely Tool for the 2026-2027 Flu Season

The timing of this approval is strategic, aimed at strengthening the medical community’s arsenal before the 2026-2027 flu season begins. Influenza remains a major public health challenge, accounting for millions of illnesses annually in the US. The introduction of a generic alternative to Xofluza is expected to foster marketplace competition, which the FDA notes is essential for making treatments more affordable and increasing overall health care access.¹



Clinical research findings published in the New England Journal of Medicine highlight the efficacy of baloxavir marboxil as a selective inhibitor of the influenza cap-dependent endonuclease, a “cap-snatching” process essential for viral replication. In phase 3 trials, this medication demonstrated a median time to symptom alleviation of 53.7 hours, compared to 80.2 hours for those receiving a placebo. Furthermore, baloxavir was found to be superior to both placebo and oseltamivir (Tamiflu; Genentech) in reducing viral load just 1 day after the initiation of the regimen.²

The Critical Role of the Pharmacist

As the first point of contact for many symptomatic patients, pharmacists will play a pivotal role in the successful deployment of generic baloxavir marboxil. Because the drug is indicated for patients who have been symptomatic for no more than 48 hours, the pharmacist’s ability to provide rapid screening and consultation is vital. Research indicates that the clinical benefit is even greater when the regimen is indicated within 24 hours of symptom onset, making the test and treat capability of community pharmacies a cornerstone of effective influenza management.²

Featured Article

Pharmacists are also responsible for ensuring proper weight-based dosing. Clinical trials utilized doses of 40 mg for patients weighing less than 80 kg and 80 mg for those weighing 80 kg or more.² Additionally, pharmacists must remain vigilant regarding contraindications, such as a history of hypersensitivity to the drug, and provide education on potential adverse effects, which most commonly include diarrhea, bronchitis, nausea, sinusitis, and headache.¹

Public Health Impact and Resistance Monitoring

Beyond individual treatment, the single-dose nature of baloxavir marboxil significantly improves patient adherence compared to multi-day antiviral regimens. However, the medical community, including pharmacists and prescribers, must monitor for treatment-emergent resistance. Clinical data show that a small percentage of recipients (approximately 9.7% in phase 3 trials) developed viral variants with reduced susceptibility to the drug.²

The FDA's approval of this generic treatment reflects a continued commitment to expanding the availability of essential medicines. By providing a cost-effective, highly potent, and easy-to-administer option, the health care system is better prepared to mitigate the impact of the upcoming flu season while reducing the burden of viral transmission across the population."

REFERENCES

1. FDA approves first single-dose generic treatment for influenza. News release. FDA. June 17, 2026. Accessed June 18, 2026. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-single-dose-generic-treatment-influenza>
2. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913-923. doi:10.1056/NEJMoa1716197